← brief for 2026-09-03 · Slowing decline

Effects and Safety of Henagliflozin on Cardiac Structure in Dialysis Patients with Heart Failure with Preserved Ejection Fraction.

Article B Peer reviewed Small trial

Key takeaways

People on dialysis who also have heart failure with a normal pumping strength have almost no proven drug options. This trial randomly assigned dialysis patients with that condition to henagliflozin, an SGLT2 inhibitor, or a dummy pill for 24 weeks, split evenly between the two groups. Neither the patients nor their doctors knew who got which, and researchers measured the heart's structure on scans along with side effects. It ran at several hospitals, but the abstract does not say how many people enrolled, and it measured heart scans over 24 weeks rather than survival or kidney outcomes.

Who did this work

Yan H · Wang W · Wu W · Li Y · Qi Y · Zhou Y · Zhang W · Liu S · Pang H · Fang Y · Li Z · Qiao Z

Source

Article · PubMed, the drug frontier · 2026 Sep 2
https://pubmed.ncbi.nlm.nih.gov/42684836/